Funding for this research was provided by:
Breast Cancer Research Foundation
National Institutes of Health/National Cancer Institute (P20 CA233307)
Received: 27 August 2020
Accepted: 20 January 2021
First Online: 4 February 2021
Ethics approval and consent to participate
: The study has been approved by the institutional review board of the University of Chicago (protocol number 16352A). All participants gave their written informed consent to participate with the possibility to withdraw from the study at any time.
: Not applicable
: O.I. Olopade is an equity stock holder of CancerIQ and Tempus. Other authors declare no conflicts of interest.